This document discusses Metabical, a new weight loss drug, and outlines objectives and strategies for its marketing and sales. In 3 sentences: Metabical is a new FDA-approved prescription weight loss drug that provides weight loss benefits with fewer side effects than other options and includes a support program. It targets overweight women aged 35-65 who want to lose 10-30 pounds and aims to provide customer satisfaction through a 12-week package and program. Pricing the drug at $150 per package is estimated to provide the highest return on investment at 307.24% based on forecasted demand of 1.242 million customers.